Pitavastatin: Itavastatin, nisvastatin, Nk 104, Nks 104, P 872441

Drugs in R and D

Volumn 3, Issue 1, 2002, Pages 58-60

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; P 872441; PITAVASTATIN; PRAVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; QUINOLINE DERIVATIVE;

ARTICLE; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG INFORMATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSFORMATION; HUMAN; HYPERLIPIDEMIA; LETHAL DOSE; LICENSING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; SIDE EFFECT; STRUCTURE ANALYSIS; ANIMAL; REVIEW;

ANIMALS; ANTILIPEMIC AGENTS; CLINICAL TRIALS; HUMANS; HYPERLIPIDEMIAS; QUINOLINES;

EID: 0036372624     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200203010-00014     Document Type: Article

References (10)

1. Kojima J, Fujino H, Abe H, et al. Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile. Biological and Pharmaceutical Bulletin. 22: 142-150, Feb 1999. Japan. [English]
2. Shibuta T, Kato Y, Akiba T, et al. Single dose toxicity studies of (+)-monocalcium bis[(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3- quinolyl]-3, 5-dihydroxy-6-heptenoate] (NK-104) in rats and dogs Pharmacometrics. 56 67-72, Oct-Nov 1998. Japan. [Japanese]
3. Kajinami K, Koizumi J. Ueda K, NK-104 Study Group, et al. Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. American Journal of Cardiology. 85: 178-183, Jan 2000. Japan. [English]
4. Nakagawa S, Aoki T, Suzuki H, et al. Pharmacological studies on NK-104, a novel potent HMG-CoA reductase inhibitor (1): inhibitory effects on the enzyme (in vitro) and sterol synthesis (in vivo) in rats and hypolipidemic effects in dogs. Japanese Journal of Pharmacology. 67 (Suppl I): 99, 1995. Japan. [English]
5. Aoki T, Nishimura H, Nakagawa S, et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase. Arzneimittel-Forschung Drug Research. 47: 904-909, Aug 1997. Japan. [English]
6. Yanagita T, Hara E, Yotsumoto H, et al. NK-104, a potent new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, enhances posttranslational catabolism of apolipoprotein B-100 and inhibits secretion of apolipoprotein B-100 and triacylglycerols from HepG2 cells. Current Therapeutic Research - Clinical and Experimental. 60: 423-434, Aug 1999. Japan. [English]
7. Kitahara M, Kanaki T, Toyoda K, Miyakoshi C, Tanaka S, et al. NK-104, a newly developed HMG-CoA reductase inhibitor, suppresses neointimal thickening by inhibiting smooth muscle cell growth and fibronectin production in balloon-injured rabbit carotid artery. Japanese Journal of Pharmacology. 77: 117-128, Jun 1998. Japan. [English]
8. Yamada N, Goto Y, Saito Y. Clinical effect of NK-104 (nisvastatin) on hyperlipidemia - double-blind comparative dose-finding study in three parallel groups. 13th International Symposium on Drugs Affecting Lipid Metabolism. : 129, 30 May 1998. Japan. [English]
9. Kajinami K, Koizumi J, Miyamoto S, FH-NK-104 Study Group, et al. Efficacy of NK-104 (Nisvastatin), a new totally synthetic HMG-CoA reductase inhibitor, in heterozygous familial hypercholesterolemia. 13th International Symposium on Drugs Affecting Lipid Metabolism. : 63, 30 May 1998. Japan. [English]
10. Yamada N, Saito Y, Akanuma Y. Influences of itavastatin, a new HMG-CoA reductase inhibitor on glucose metabolism and LDL size in patients with hyperlipidemia and NIDDM. Diabetes. 49 (Suppl 1): 422May 2000. Japan. [English]